Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
Furthermore, when larger group testing occurs, this allows researchers to identify and ensure that any improvements resulting from the intervention occurs for as many people as possible and are not just occurring in one individual.
Ahead of the J.P. Morgan Health Conference in San Francisco in January 2023, Australian Health Journal met with Clinials CEO & Founder Maree Beare about developing the next generation recruitment platform and digital marketing service for clinical research. Maree talks about the reasons why clinical trials can fail and the importance of bringing participants much more closer to researchers.
With this need, the Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
Supporting CRO’s, sites and sponsors, the Clinials platform uses AI to convert complex trial protocol into plain language and pre-screening questions. This gives researchers the tools to communicate with their participants meaningfully. The plain language text can be used in a variety of situations like researcher led advertising, landing pages and plain language summaries.
You Might also like
-
Driven by purpose
Dr Joe DusseldorpDr Joe Dusseldorp is an Australian surgeon who was first in the country to implant custom 3D printed ears in a number of young Australian children born with a congenital abnormality called microtia. His family ancestry is unique in having 5 generations of medical doctors. Driven by a deeper purpose in treating patients, Dr Dusseldorp’s segment continues Australian Health Journal’s People in Health Care series.
-
Foundation outlines breast cancer research strategy
Australian Health Journal met with Associate Professor Cleola Anderiesz, CEO of the National Breast Cancer Foundation to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.
-
Co-design, adoption and interoperability
In October CEBIT AUSTRALIA held it’s yearly technology related conference. Australian Health Journal’s reporter Anne Dao spoke with health technology thought leaders on what needs to be consider in Co-Design, Adoption and Interoperability of technology aided healthcare delivery